Clinical Trials Directory

Trials / Completed

CompletedNCT06892418

Impact of Ketoflex 12/3 Diet on Parkinson's Disease Symptoms: A Clinical Study

A Clinical Study on the Effects of Ketoflex 12/3 Diet on Motor and Non-Motor Symptoms in Patients With Parkinson's Disease

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Istanbul Medipol University Hospital · Academic / Other
Sex
All
Age
40 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This study aims to investigate the effects of the Ketoflex 12/3 diet on motor and non-motor symptoms in patients with Parkinson's disease. Participants will follow the Ketoflex 12/3 dietary regimen, and their cognitive function, motor symptoms, sleep patterns, gastrointestinal health, and overall well-being will be assessed through standardized clinical scales. The study will help determine whether a plant-based ketogenic diet combined with intermittent fasting can have a beneficial impact on Parkinson's disease progression.

Detailed description

Parkinson's disease is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. Emerging evidence suggests that dietary interventions, particularly ketogenic diets and intermittent fasting, may play a role in neuroprotection and symptom management. This study investigates the effects of the Ketoflex 12/3 diet, a plant-based ketogenic dietary approach combined with intermittent fasting, on Parkinson's disease progression. Clinical assessments will include Unified Parkinson's Disease Rating Scale (UPDRS), Mini-Mental State Examination (MMSE), depression and anxiety scales, sleep quality assessments, and gastrointestinal health evaluations. The study aims to provide new insights into the potential benefits of metabolic-based nutritional interventions in Parkinson's disease patients.

Conditions

Interventions

TypeNameDescription
BEHAVIORALKetoflex 12/3 DietA plant-based ketogenic diet combined with intermittent fasting (12/3)

Timeline

Start date
2024-03-30
Primary completion
2024-10-30
Completion
2024-11-30
First posted
2025-03-24
Last updated
2025-04-02

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06892418. Inclusion in this directory is not an endorsement.